Business
Notice of Cipher Pharmaceuticals Q2 2018 Conference Call
Notice of Cipher Pharmaceuticals Q2 2018 Conference Call Canada NewsWire MISSISS...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nNotice of Cipher Pharmaceuticals Q2 2018 Conference Call\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:1pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nMISSISSAUGA, ON, July 23, 2018\n\n\n\nMISSISSAUGA, ON, July 23, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) (\"Cipher\" or \"the Company\") today announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer. Cipher will issue its financial results on the morning of August 10, 2018.  \n\nCONFERENCE CALL DETAILS\n\n\n\n\nDATE:\n\n\nFriday, August 10, 2018\n\n\n\nTIME:\n\n\n8:30 a.m. EDT\n\n\n\nDIAL IN NUMBER:\n\n\n(416) 764-8609 or (888) 390-0605\n\n\n\nCONFERENCE ID:\n\n\n25005708\n\n\n\nREPLAY:\n\n\n(888) 390-0541 (playback code 005708)\n\n\n\n\nAvailable until midnight (EST) August 17, 2018\n\n\n\nWEBCAST:\n\n\nThe audio webcast can be accessed at http://cipher.investorroom.com/ under Investor Relations or at https://bit.ly/2mD9mUa\n\n \n\nAbout Cipher Pharmaceuticals Inc.Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com. \nSOURCE Cipher Pharmaceuticals ...